-
ArticlePublication 2015Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) …
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) that at the time of this study was approved for persons age 50+. The authors used a Markov model to simulate adults aged 50 years over a lifetime from a societal perspective; outcomes included the number of HZ and postherpetic neuralgia (PHN) cases prevented and the incremental cost per quality-adjusted life-year (QALY) saved. Their focus was on the cost effectiveness…
State-Transition | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | North America -
ArticlePublication 2013Vaccination against Herpes Zoster and Postherpetic Neuralgia in France: A Cost-Effectiveness Analysis
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for …
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for the 65 year + population in France. The authors compared vaccinating all adults over 65 years versus adults from 70-79 years, over their lifetimes, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol 5D) utilities from the literature. Results showed incremental cost-effective ratios d between €9513 and €12,304 per quality-adjusted life…
State-Transition | Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Europe
2 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic